Impact of Other Cancers After Immunochemotherapy in CLL Patients
Author Information
Author(s): Stocker Nicolas, Alsuliman Tamim, Corre Elise, Ricard Laure, Kaoui Fazia, Coppo Paul, Brissot Eolia, Dulery Remy, Banet Anne, Van de Wyngaert Zoé, Legrand Ollivier, Bonnin Agnès, Mohty Mohamad, Malard Florent, Marjanovic Zora
Primary Institution: Saint-Antoine Hospital, Paris, France
Hypothesis
What is the incidence and impact of other malignancies after immunochemotherapy by fludarabine, cyclophosphamide, and rituximab in chronic lymphocytic leukemia patients?
Conclusion
Patients with chronic lymphocytic leukemia who developed other malignancies after treatment had significantly shorter survival compared to those without.
Supporting Evidence
- 31% of patients developed other malignancies after treatment.
- The median time to onset of other malignancies was 61.8 months.
- Patients with other malignancies had a median overall survival of 104 months compared to 149 months for those without.
Takeaway
People with a type of blood cancer called CLL can get other cancers after treatment, which can make it harder for them to live longer.
Methodology
This was a retrospective study analyzing 108 CLL/SLL patients treated with FCR immunochemotherapy, assessing the incidence and impact of other malignancies.
Potential Biases
The retrospective nature of the study and incomplete documentation of causes of death may introduce bias.
Limitations
The study had incomplete data which may have introduced bias.
Participant Demographics
The median age of participants was 63 years, with 64% male and 91% diagnosed with chronic lymphocytic leukemia.
Statistical Information
P-Value
0.02
Confidence Interval
95%CI, 102-166
Statistical Significance
p=0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website